Carl Steele, DO
Family Medicine · Port Clinton, OHNPI 1457469751
Payments from drug & device makers
Across 103 payments — averaging $16.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$415
- Novo Nordisk$216
- Corcept Therapeutics$185
- AbbVie$139
- Lilly USA, LLC$123
- Astellas Pharma US Inc$95
- plus $546 from 17 others
What the payments were for
- Food & beverage$1,718100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $415 |
| Novo Nordisk | 13 | $216 |
| Corcept Therapeutics | 10 | $185 |
| AbbVie | 7 | $139 |
| Lilly USA, LLC | 7 | $123 |
| Astellas Pharma US Inc | 7 | $95 |
| Amarin Pharma, Inc. | 5 | $81 |
| Amgen | 3 | $55 |
| Acella Pharmaceuticals, LLC | 3 | $51 |
| Phathom Pharmaceuticals, Inc. | 2 | $46 |
| GSK | 3 | $46 |
| Pfizer | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Tolmar, Inc. | 1 | $26 |
| Exact Sciences | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Merck | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$1,718 in reported general payments places this provider in the 70th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 46 | $462 |
| ValacyclovirValacyclovir Hcl | 15 | $299 |
| Lisinopril | 45 | $285 |
| Tamsulosin Hcl | 22 | $258 |
| Levothyroxine Sodium | 26 | $211 |
| Losartan Potassium | 16 | $182 |
| Famotidine | 16 | $168 |
| Warfarin Sodium | 13 | $147 |
| Metformin Hcl ErMetformin Hcl | 16 | $108 |
| Lisinopril-HydrochlorothiazideLisinopril/Hydrochlorothiazide | 15 | $97 |
| Amlodipine Besylate | 18 | $90 |
| Simvastatin | 19 | $69 |
| Metoprolol Succinate | 12 | $65 |
| Metoprolol Tartrate | 14 | $57 |
| Prednisone | 17 | $30 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Port Clinton
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.